Literature DB >> 26017221

Inhibition of Inflammation and Bone Erosion by RNA Interference-Mediated Silencing of Heterogeneous Nuclear RNP A2/B1 in Two Experimental Models of Rheumatoid Arthritis.

Sonja Herman1, Anita Fischer1, Jessy Presumey2, Markus Hoffmann1, Marije I Koenders3, Virginie Escriou4, Florence Apparailly2, Guenter Steiner5.   

Abstract

OBJECTIVE: The nuclear protein heterogeneous nuclear RNP A2/B1 (hnRNP A2/B1) is involved in posttranscriptional regulation of gene expression. It is constitutively expressed in lymphoid organs and highly up-regulated in the synovial tissue of patients with rheumatoid arthritis (RA), who may also generate autoantibodies to this protein. This study was undertaken to investigate the potential involvement of hnRNP A2/B1 in the pathogenesis of autoimmune arthritis, by silencing hnRNP A2/B1 expression in 2 animal models of RA.
METHODS: Collagen-induced arthritis (CIA) and the K/BxN serum-transfer model were used as animal models of RA. Efficient silencing of hnRNP A2/B1 was achieved using a liposome-based carrier system for delivery of small interfering RNAs. Expression of hnRNP A2/B1 was analyzed by flow cytometry, reverse transcription-quantitative polymerase chain reaction, Western blotting, and immunohistochemistry. The number of osteoclasts was determined by tartrate-resistant acid phosphatase staining. Cytokine levels and anticollagen antibody levels were measured by enzyme-linked immunosorbent assay.
RESULTS: Efficient silencing of hnRNP A2/B1 was achieved in all lymphoid organs. In both experimental models, the incidence and severity of arthritis were largely reduced and bone erosion was not detectable as compared to the control groups. Down-modulation of hnRNP A2/B1 significantly interfered with the production of proinflammatory cytokines from monocyte/macrophages, but not from T cells. Consistent with these findings, production of T cell cytokines was not impaired when cells were restimulated in vitro with type II collagen. Furthermore, levels of anticollagen antibodies were not affected by hnRNP A2/B1 silencing.
CONCLUSION: Our findings suggest that hnRNP A2/B1 has an important role in regulation of the innate immune system, especially at the level of monocyte/macrophage activation. Therefore, down-modulation of hnRNP A2/B1 seems to affect primarily the effector phase of autoimmune arthritis.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26017221     DOI: 10.1002/art.39223

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  5 in total

Review 1.  Applications of RNA interference in the treatment of arthritis.

Authors:  Muhammad Farooq Rai; Hua Pan; Huimin Yan; Linda J Sandell; Christine T N Pham; Samuel A Wickline
Journal:  Transl Res       Date:  2019-07-10       Impact factor: 7.012

2.  HnRNPL inhibits the osteogenic differentiation of PDLCs stimulated by SrCl2 through repressing Setd2.

Authors:  Xiaoshi Jia; Richard J Miron; Chengcheng Yin; Hudi Xu; Tao Luo; Jiwei Wang; Rong Jia; Min Wu; Yufeng Zhang; Yuhong Li
Journal:  J Cell Mol Med       Date:  2019-02-12       Impact factor: 5.310

Review 3.  Non-coding RNA delivery for bone tissue engineering: Progress, challenges, and potential solutions.

Authors:  Shiyao Guan; Zhen Zhang; Jun Wu
Journal:  iScience       Date:  2022-07-20

Review 4.  siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.

Authors:  Saman Sargazi; Rabia Arshad; Reza Ghamari; Abbas Rahdar; Ali Bakhshi; Sonia Fathi Karkan; Narges Ajalli; Muhammad Bilal; Ana M Díez-Pascual
Journal:  Cell Biol Int       Date:  2022-07-13       Impact factor: 4.473

5.  Anti-Inflammatory Action of Heterogeneous Nuclear Ribonucleoprotein A2/B1 in Patients with Autoimmune Endocrine Disorders.

Authors:  Antonina Coppola; Patrizia Cancemi; Laura Tomasello; Valentina Guarnotta; Maria Pitrone; Valentina Failla; Salvatore Cillino; Salvatore Feo; Giuseppe Pizzolanti; Carla Giordano
Journal:  J Clin Med       Date:  2019-12-19       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.